No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Amphastar Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
Wells Fargo Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Cuts Target Price to $35
Amphastar Pharmaceuticals | 10-Q: Quarterly report
Amphastar Pharmaceuticals Is Maintained at Overweight by Wells Fargo